GlassScriptPhysician profile
Neil M Barth
NPI 1245379858
$2,958.36
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $104 · 2021: $2,435.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,519.68 | 2019-2021 | |
| Janssen Biotech, INC. | $155.34 | 2019 | |
| Pfizer INC. | $94.38 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $83.48 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $54.31 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $15.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.06 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Barth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.